Clinical Pharmacological Review of Cefepime/Taniborbactam: A New Type β-lactamase Inhibitor Complex Formulation
Keywords:
β-lactamases, Cefepime, Taniborbactam, Pharmacodynamics, PharmacokineticsAbstract
Bacterial resistance is increasing exponentially worldwide, especially in carbapenem-resistant Gram-negative bacteria, but effective therapeutic drugs are very limited. Taniborbactam is a novel cyclic borate ester β-lactamase inhibitor. It has a strong inhibitory effect on serine and metallo-β-lactamases (Ambler classes A, B, C, and D). Currently, taniborbactam is combined with cefepime for new drug development, with the potential to address this medication demand. This article provides a review of the mechanism, pharmacodynamics, and pharmacokinetic clinical studies of cefepime/taniborbactam.
References
Losito AR, Raffaelli F, Del Giacomo P, et al., 2022, New Drugs for the Treatment of Pseudomonas aeruginosa Infections With Limited Treatment Options: A Narrative Review. Antibiotics, 11(5): 579.
Wu SP, Xu HY, Hu XD, 2019, Beta-Lactamase Inhibitor: US10479805.
Krajnc A, Brem J, Hinchliffe P, et al., 2019, Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases. Journal of Medicinal Chemistry, 62(18): 8544–8556.
Venatorx Pharmaceuticals, Inc., 2019, Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects, visited January 28, 2024, https://clinicaltrials.gov/study/NCT03870490.
Venatorx Pharmaceuticals, Inc., 2019, VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment, visited January 28, 2024, https://clinicaltrials.gov/study/NCT03690362.
Liu X, Li B, Chen Y, et al., 2024, Research Progress on Therapeutic Drug Monitoring of Ceftazidime/Avibactam. Chinese Journal of New Drugs, 33(9): 904–910.
Venatorx Pharmaceuticals, Inc., 2018, VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers, visited January 28, 2024, https://clinicaltrials.gov/study/NCT03332732.
Venatorx Pharmaceuticals, Inc., 2021, Safety and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy Subjects, visited January 28, 2024, https://clinicaltrials.gov/study/NCT04951505.
Venatorx Pharmaceuticals, Inc., 2022, Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections, visited January 28, 2024, https://clinicaltrials.gov/study/NCT03840148.
Venatorx Pharmaceuticals, Inc., 2023, Cefepime-Taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP, visited January 28, 2024, https://clinicaltrials.gov/study/NCT06168734.
Liu B, Trout REL, Chu GH, et al., 2020, Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-Lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. Journal of Medicinal Chemistry, 63(6): 2789–2801.
Hamrick JC, Docquier JD, Uehara T, et al., 2020, VNRX-5133 (Taniborbactam): A Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 64(3): e01963–e01919.
Ono D, Mojica MF, Bethel CR, et al., 2024, Structural Role of K224 in Taniborbactam Inhibition of NDM-1. Antimicrobial Agents and Chemotherapy, 68(2): e0133223.
Hernández-García M, García-Castillo M, Ruiz-Garbajosa P, et al., 2022, In Vitro Activity of Cefepime-Taniborbactam Against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain. Antimicrobial Agents and Chemotherapy, 66(3): e0216121.
Mushtaq S, Vickers A, Doumith M, et al., 2021, Activity of β-Lactam/Taniborbactam (VNRX-5133) Combinations Against Carbapenem-Resistant Gram-Negative Bacteria. Journal of Antimicrobial Chemotherapy, 76(1): 160–170.
Piccirilli A, Segatore B, Brisdelli F, et al., 2021, Potent Inhibitory Activity of Taniborbactam Towards NDM-1 and NDM-1 Q19X Mutants, and In Vitro Activity of Cefepime/Taniborbactam Against MBL-Producing Enterobacterales. International Journal of Antimicrobial Agents, 57(1): 106228.
Wang XJ, Zhao CJ, Wang Q, et al., 2020, Erratum to: In Vitro Activity of the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133), in Combination With Cefepime or Meropenem, Against MDR Gram-Negative Bacterial Isolates From China. Journal of Antimicrobial Chemotherapy, 75(7): 2019.
Kloezen W, Melchers RJ, Georgiou PC, et al., 2021, Activity of Cefepime in Combination With the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) Against Extended-Spectrum-β-Lactamase-Producing Isolates in In Vitro Checkerboard Assays. Antimicrobial Agents and Chemotherapy, 65(4): e02338-e02320.
Abdelraouf K, Abuhussain SA, Nicolau DP, 2020, In Vivo Pharmacodynamics of New-Generation β-Lactamase Inhibitor Taniborbactam (Formerly VNRX-5133) in Combination With Cefepime Against Serine-β-Lactamase-Producing Gram-Negative Bacteria. Journal of Antimicrobial Chemotheraphy, 75(12): 3601–3610.
Lasko MJ, Nicolau DP, Asempa TE, 2022, Clinical Exposure-Response Relationship of Cefepime/Taniborbactam Against Gram-Negative Organisms in the Murine Complicated Urinary Tract Infection Model. Journal of Antimicrobial Chemotheraphy, 77(2): 443–447.
Abdelraouf K, Nicolau DP, 2023, In Vivo Pharmacokinetic/Pharmacodynamic Evaluation of Cefepime/Taniborbactam Combination Against Cefepime-Non-Susceptible Enterobacterales and Pseudomonas Aeruginosa in a Murine Pneumonia Model. Journal of Antimicrobial Chemotheraphy, 78(3): 692–702.
Weiss W, Pulse M, Nguyen P, et al., 2018, Efficacy of Cefepime/VNRX-5133, a Novel Broad-Spectrum β-Lactamase Inhibitor, in a Murine Bacteraemia Infection Model With Carbapenem-Resistant Enterobacteriaceae (CREs), UNT Health Science Center, European Congress of Clinical Microbiology and Infectious Diseases, Madrid.
Dowell JA, Dickerson D, Henkel T, 2021, Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor. Antimicrobial Agents and Chemotheraphy, 65(11): e0105321.
Dowell JA, Marbury TC, Smith WB, et al., 2022, Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) With Cefepime in Subjects With Various Degrees of Renal Impairment. Antimicrobial Agents and Chemotheraphy, 66(9): e0025322.
Wagenlehner FM, Gasink LB, McGovern PC, et al., 2024, Cefepime-Taniborbactam in Complicated Urinary Tract Infection. The New England Journal of Medicine, 390(7): 611–622.